The Study on the Clinical Utility of Liquid Biopsy in Breast Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Peking Union Medical College
- Enrollment
- 200
- Primary Endpoint
- the enumeration of circulating tumor biomarkers
- Last Updated
- 9 years ago
Overview
Brief Summary
Through this prospective clinical trial,the investigators will focus on the relationship between circulating tumor biomarkers (i.e. circulating tumor cells, circulating tumor DNA and other biomarkers) and the status of primary tumor to discuss its application for assessing prognosis and individualized therapeutic direction. Moreover, the relationship between the circulating tumor cell subpopulations based on epithelial-mesenchymal transition and molecular pathological classification of breast cancer will be determined, which may enable the determination of the value of its application in therapeutic decision making.
Investigators
Fei Ma
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,China
Peking Union Medical College
Eligibility Criteria
Inclusion Criteria
- •Female patients aged ≥18 years with histologically confirmed breast cancer.
- •The patients diagnosed with breast cancer for the first time, including postoperative patients within one month and the patients diagnosed with Stage IV breast cancer for the first time.
Exclusion Criteria
- •The patients who has begun medication for breast cancer.
Outcomes
Primary Outcomes
the enumeration of circulating tumor biomarkers
Time Frame: up to 2 years